Amgen Awards MBC BioLabs Golden Tickets to Regencor and Nitrome Biosciences
Amgen and MBC BioLabs announced that Regencor and Nitrome Biosciences have each been awarded an Amgen Golden Ticket to MBC BioLabs. The companies receive priority admission or renewal for one year of lab bench space and access to core facilities at the MBC BioLabs life sciences incubator, as well as connections to Amgen's scientific and business leaders to help advance their scientific programs. Amgen has been sponsoring MBC BioLabs since 2016 to assist high-potential and innovative early-stage life science and biotech companies in their efforts to accelerate the development of new therapies to improve human health. Full Press Release.
An early taste of Wild Type Salmon
Skyrocketing demand is depleting oceans and fueling a problematic fish-farming industry. The next chapter of fish production, beyond even land-based farming, is already being written—by scientists. San Francisco (and MBC BioLabs)-based Wild Type is hoping that, as with the rise of meat substitutes lab-grown fish won't be far behind.
On a recent Sunday evening in Portland, Oregon, a group of Wild Type employees, investors, chefs, local restaurant owners and friends gathered at Olympia Oyster Bar for the first full-scale service of the company's product, straight from the lab. Read Full Article.
BillionToOne Launches Prenatal Blood Screeener for Cystic Fibrosis, SMA and Sickle Cell
BillionToOne has launched its first product for commercial and clinical use—a prenatal screening test for cystic fibrosis, spinal muscular atrophy and sickle cell disease.
The company's molecule-counting diagnostic test, Unity, searches for cell-free fetal DNA using blood drawn from the mother. The Menlo Park, California-based BillionToOne is planning a limited initial commercial launch before a wider rollout set for later this year. Read Full Article.
Trilo Therapeutics is a seed-stage company focused on the discovery of novel inhibitors of protein-protein interactions for therapeutic purposes. Trilo's platform of peptidomimetic binders allows for the targeted inhibition of disease-causing proteins, for the treatment of cancer, autoimmune diseases, infectious diseases, and others.